{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9599","statisticalComment":"Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet","statisticalMethod":"Pearson's Chi-squared test"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2470","statisticalComment":"Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands","statisticalMethod":"Pearson's Chi-squared test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"31"}]}],"title":"Feet, 0-Not at all"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"16"}]}],"title":"Feet, 1-A little bit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"17"}]}],"title":"Feet, 2-Somewhat"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"11"}]}],"title":"Feet, 3-Quite a bit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}]}],"title":"Feet, 4-Very much"},{"categories":[{"measurements":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"43"}]}],"title":"Hands, 0-Not at all"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"21"}]}],"title":"Hands, 1-A little bit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}]}],"title":"Hands, 2-Somewhat"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"3"}]}],"title":"Hands, 3-Quite a bit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}]}],"title":"Hands, 4-Very much"}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"description":"A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of \"not at all\" (0) to \"very much\" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 (\"not at all\") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 (\"a little bit\").","groups":[{"description":"Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.","id":"OG000","title":"Non-gBRCA Niraparib"},{"description":"Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression","id":"OG001","title":"Non-gBRCA Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-treat Population. Only those participants with data available at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"At Cycle 4 (Each cycle was of 28 days)","title":"Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 4","type":"SECONDARY","unitOfMeasure":"Participants"}